Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments | Zendy

Ethel D. Weld | Zendy; Jacqueline Astemborski | Zendy; Gregory D. Kirk | Zendy; Mark Sulkowski | Zendy; Stephanie Katz | Zendy; Richard E. Rothman | Zendy; Sunil S. Solomon | Zendy; Gail Matthews | Zendy; Yu Hsiang Hsieh | Zendy; Malvika Verma | Zendy; Giovanni Traverso | Zendy; Susan Swindells | Zendy; Andrew Owen | Zendy; Jordan J. Feld | Zendy; Charles Flexner | Zendy; Shruti H. Mehta | Zendy; David L. Thomas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments

Author(s) -

Ethel D. Weld,

Jacqueline Astemborski,

Gregory D. Kirk,

Mark Sulkowski,

Stephanie Katz,

Richard E. Rothman,

Sunil S. Solomon,

Gail Matthews,

Yu Hsiang Hsieh,

Malvika Verma,

Giovanni Traverso,

Susan Swindells,

Andrew Owen,

Jordan J. Feld,

Charles Flexner,

Shruti H. Mehta,

David L. Thomas

Publication year - 2021

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciab913

Subject(s) - medicine , pill , hepatitis c virus , hepatitis c , implant , surgery , virus , immunology , pharmacology

Whereas safe, curative treatments for hepatitis C virus (HCV) have been available since 2015, there are still 58 million infected persons worldwide, and global elimination may require new paradigms. We sought to understand the acceptability of approaches to long-acting HCV treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research